BACKGROUND: Active surveillance (AS) protocols for low-risk prostate cancer (PCa) generally include repeat prostate biopsies at predefined follow-up intervals. OBJECTIVE: To study the outcome of routinely obtained 1-yr repeat biopsies and factors predicting reclassification to higher risk, to contribute to risk stratification for men on AS. DESIGN, SETTING, AND PARTICIPANTS: We analysed men with low-risk PCa (clinical stage 64 T2, prostate-specific antigen (PSA) 64 10 ng/ml, PSA density <0.2 ng/ml per millilitre, one or two positive biopsy cores, and Gleason score 64 6) who had been included in a prospective AS protocol. INTERVENTIONS: PSA was measured 3-monthly and the first volume-dependent repeat biopsy was scheduled 1 yr after...
Background: The optimal interval for repeat biopsy during active surveillance (AS) for prostate canc...
textabstractBackground: Most men with elevated levels of prostate-specific antigen (PSA) do not have...
BACKGROUND: Most men with elevated levels of prostate-specific antigen (PSA) do not have prostate ca...
Background. Little evidence is available to determine which patients should undergo repeat biopsy af...
Purpose: We hypothesized that there might be a higher incidence of low-risk prostate cancer (PCa) in...
Background: The optimal interval for repeat biopsy during active surveillance (AS) for prostate canc...
BACKGROUND: The optimal interval for repeat biopsy during active surveillance (AS) for prostate canc...
BackgroundA better understanding of the independent predictors of disease progression for prostate c...
Purpose: We compare the ability of total prostate specific antigen (PSA), percent free PSA, PSA dens...
PURPOSE: We developed a predictive model that incorporates clinical data and prostate specific antig...
Objective: To study the risk of serial prostate biopsies on complications in men on active surveilla...
Background: The aim of our study was to identify the optimal predictor of prostate cancer among seve...
PurposeWe assessed whether an association exists between a change in prostate specific antigen and b...
Study Type - Diagnosis (exploratory cohort) Level of Evidence 2b OBJECTIVE To describe the follow-up...
BACKGROUND: Most men with elevated levels of prostate-specific antigen (PSA) do not have prostate ca...
Background: The optimal interval for repeat biopsy during active surveillance (AS) for prostate canc...
textabstractBackground: Most men with elevated levels of prostate-specific antigen (PSA) do not have...
BACKGROUND: Most men with elevated levels of prostate-specific antigen (PSA) do not have prostate ca...
Background. Little evidence is available to determine which patients should undergo repeat biopsy af...
Purpose: We hypothesized that there might be a higher incidence of low-risk prostate cancer (PCa) in...
Background: The optimal interval for repeat biopsy during active surveillance (AS) for prostate canc...
BACKGROUND: The optimal interval for repeat biopsy during active surveillance (AS) for prostate canc...
BackgroundA better understanding of the independent predictors of disease progression for prostate c...
Purpose: We compare the ability of total prostate specific antigen (PSA), percent free PSA, PSA dens...
PURPOSE: We developed a predictive model that incorporates clinical data and prostate specific antig...
Objective: To study the risk of serial prostate biopsies on complications in men on active surveilla...
Background: The aim of our study was to identify the optimal predictor of prostate cancer among seve...
PurposeWe assessed whether an association exists between a change in prostate specific antigen and b...
Study Type - Diagnosis (exploratory cohort) Level of Evidence 2b OBJECTIVE To describe the follow-up...
BACKGROUND: Most men with elevated levels of prostate-specific antigen (PSA) do not have prostate ca...
Background: The optimal interval for repeat biopsy during active surveillance (AS) for prostate canc...
textabstractBackground: Most men with elevated levels of prostate-specific antigen (PSA) do not have...
BACKGROUND: Most men with elevated levels of prostate-specific antigen (PSA) do not have prostate ca...